Early screening and early diagnosis is an effective way to reduce the mortality of malignant tumors. Genetron Health has made a key breakthrough in the field of early screening of liver cancer. In the future, we will optimize and expand to early screening of multiple cancer species based on the existing technical platform, and accelerate the medical translation to clinical practices, in order to benefit the public sooner.
Genetron Health's products and services cover multiple types of cancer, by detecting unique gene mutations in patients, assisting patients in selecting targeted drugs and chemotherapeutics, evaluating the efficacy of immunotherapy, dynamically monitoring the progress of drug resistance and other diseases treatment, and assisting in formulating and optimizing clinical trials treatment plan to achieve personalized diagnosis and treatment.
As a pioneer in the field of precision diagnosis and treatment of oncology in China, Genetron Health focuses on the overall solution service for the full cancer cycle, and can provide pharmaceutical company partners with more accurate test plan design and efficient implementation, integrated companion diagnostic development services and multi-dimensional high-throughput screening of potential drug targets, all-round support for precision drug research and development.
Genetron Health has two medical device production bases that have passed ISO13485:2016 and ISO9001:2015 system certifications, and five clinical laboratories in Beijing (CAP & ISO 15189 accredited, CLIA certified), Shanghai, Chongqing, Guangzhou and Maryland, U.S (CLIA certified).